Bausch + Lomb Corporation

BLCO Healthcare Medical Instruments & Supplies

Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.

Revenue
+7.34%
EPS
+222.4%
Free cash flow
+182.5%
Total debt
+2.93%

Quarter to September 2026, against a year earlier

19.69 0.23 −1.15%
Market cap
$7.1B
P/E
0.0×
Fwd P/E
749×
Dividend yield
—
F-score
3/9
Altman Z
0.87
Beneish M
−2.52
Dividend safety
n/a

Bausch + Lomb Corporation 10-Q filed Oct 28, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:25 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 29, 2026: 13 added · 7 removed · 63 modified; 36 with only figures updated

  1. Modified · split · OVERVIEW

    Bausch + Lomb understands We understand that BHC continues to believe that completing the Separation, which may include the monetization of all or a portion of BHC’s ownership interest in Bausch + Lomb, the sale of the Company (a “Sale Transaction”), the transfer of all or a portion of BHC’s remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the “Distribution”), or a combination thereof, makes strategic sense and that BHC continues to evaluate all relevant factors and considerations relatedrelating to completing the Separation, including those factors described its investment in BHC’s public filings. The Distribution is subject to the achievement of targeted debt leverage ratios and the completion of the Separation is subject to the receipt of any applicable shareholder and other necessary approvals and other factors and is subject to various risk factors. There can be no assurance that the Separation will be consummatedBausch + Lomb, the form including any such consummated Separation would take or that a Distribution or Sale Transaction will occur as part completion of that Separation or that even if consummated, we will realize the anticipated benefits from the full Separation. For additional information on the risks related to the SeparationHowever, see Item 1A. “Risk Factors — Risks Relating to the Separation” of our Annual Report. There there can be no assurance that the Separation will be consummated, the form any such consummated Separation would take or that a Distribution or Sale Transaction will occur as part of that Separation or that, even if consummated, we will realize the anticipated benefits from the Separation.